Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.

DCV+SOF±RBV, VEL/SOF±RBV both effective against genotypes 2, 3 hepatitis C

01 Jan 2019

Treatment regimens containing daclatasvir plus sofosbuvir with or without ribavirin (DCV+SOF±RBV) and the velpatasvir–sofosbuvir combination with or without ribavirin (VEL/SOF±RBV) deliver comparable efficacies against genotypes 2 and 3 hepatitis C virus (HCV) infection, a new study has shown.

Researchers evaluated 44 and 256 patients with genotype 2 HCV who received DVC+SOF±RBV (mean age 62.5±7.0 years 100 percent male) and VEL/SOF±RBV (mean age 63.4±6.4 years; 98.4 percent male), respectively. A total of 514 and 455 genotype 3 HCV patients were also included and were given DCV+SOF±RBV (mean age 60.9±5.6 years; 98.2 percent male) and VEL/SOF±RBV (mean age 61.0±6.7 years; 97.1 percent male), respectively.

Data for sustained virologic response (SVR) were available for 2,774 genotype 2 patients. Among these, 93.9 percent achieved SVR, the rates of which were comparable among those who were given DCV+SOF±RBV (88.1 percent) and VEL/SOF+RBV (89.5 percent; p=1.00). The use of RBV did not lead to statistical improvements in SVR rates.

In comparison, SVR was reported in 90.2 percent of 2,626 genotype 3 patients, for whom the pertinent data were available. Rates were likewise comparable between DCV+SOF±RBV (88.1 percent) and VEL/SOF±RBV (86.4 percent; p=0.51) patients.

Multivariate models showed that a decompensated disease (odds ratio [OR], 0.68; 95 percent CI, 0.47–0.99; p=0.04) and prior HCV treatment (OR, 0.51; 0.36–0.72; p<0.001) significantly reduced the likelihood of SVR in genotype 3 patients. In those with genotype 2 disease, only age <55 years exerted this effect (OR, 0.45; 0.27–0.77; p=0.002).

“The results support current evidence-based guidelines for the use of either DCV+SOF or VEL/SOF as effective treatment options for genotypes 2 and 3,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.